Sculptor Capital’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Sculptor Capital’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-300,538	Closed	-$3.04M	–	871
2022 Q4	$3.04M	Hold	300,538	–	–	0.05%	311
2022 Q3	$2.98M	Buy	300,538 +298	+0.1%	+$2.94K	0.04%	462
2022 Q2	$2.97M	Buy	300,240 +240	+0.1%	+$2.35K	0.03%	503
2022 Q1	$2.96M	Hold	300,000	–	–	0.02%	543
2021 Q4	$2.95M	Hold	300,000	–	–	0.03%	509
2021 Q3	$2.92M	Hold	300,000	–	–	0.02%	419
2021 Q2	$2.9M	Hold	300,000	–	–	0.02%	439
2021 Q1	$2.92M	Buy	+300,000	New	+$2.91M	0.02%	372

Sculptor Capital's BIOT Position: Q1 2023 in Review

Sculptor Capital sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 300,538 shares — an estimated $3.04M sold.

Sculptor Capital first reported a position in BIOT in Q1 2021 and held it in 8 quarters. The position peaked at $3.04M in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Sculptor Capital reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Sculptor Capital sold 300,538 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $3.04M.
Sculptor Capital first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q1 2021 and held it in 8 quarters.
Sculptor Capital's Biotech Acquisition Company Class A Ordinary Shares position peaked at $3.04M in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Sculptor Capital's 13F filing for Q1 2023, filed 16 May 2023.